ClinicalTrials.gg
CompletedNCT06465485STEPUpdated Sep 3, 2026

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

A Phase 3 interventional study of Benralizumab in Severe Eosinophilic Asthma, sponsored by AstraZeneca. Completed at 74 sites in China. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Non-randomized
Ages
12 Years to 75 Years
Sex
All
01

Study summary

This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to maintain asthma control in Chinese patients.

Read the detailed description

The study population will be approximately 440-520 patients on MD/HD ICS/LABA with and without LTRA or LAMA or theophylline and meeting study inclusion and exclusion criteria in China. After patients sign the informed consent, they will undergo a screening visit (Visit 1, Week -1 to Week 0) to assess eligibility criteria. Patients who meet eligibility criteria and complete study baseline assessments will enter the study and receive the first dose of benralizumab at visit 2 (Week 0).

The benralizumab treatment includes 4 phases: Induction Phase (16 weeks), Reduction Phase (24 weeks), Maintenance Phase (16 weeks) and Follow-up Phase (4 weeks). After initiation of benralizumab 30 mg administered subcutaneously every 4 weeks (Q4W) for the first 3 doses (Visits 2 to 4), then every 8 weeks (Q8W) thereafter.

02

Conditions studied

  • Severe Eosinophilic Asthma
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

1.Provision of informed consent prior to any study-specific procedures. Written informed consent, and assent when applicable for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent[s]/guardian[s]) and according to international guidelines and/or applicable local guidelines.

Age 2. Patient must be aged 12-75 years old, inclusively, at the time of Visit 1(Week -1 to Week 0) For those patients, who are 17 on the day of Visit 1(Week -1 to Week 0) but will turn 18 after this day, will be considered an adolescent for the purposes of this study.

Type of Patient and Disease Characteristics 3. Documented history of physician-diagnosed asthma prior to Visit 1

  • The documentation requirements for demonstrating pulmonary function reversibility are as follows for Screening (Visit 1, Week -1 to Week 0):

    1. For patients diagnosed with asthma ≥1 year prior to enrolment, pulmonary function reports from within 12 months prior to Visit 1 are required: i. If pre- or post-bronchodilator /FVC ≥70% in reports within 12 months prior to Visit 1: Only objective records of prior reversibility testing confirming asthma diagnosis are required. ii. If both pre- and post-bronchodilator FEV1/FVC \<70% in reports within 12 months prior to Visit 1: Must provide objective documentation within 12 months prior to Visit 1 of any of the following:

      • Positive bronchodilator response test, or
      • Positive bronchial provocation test, or
      • Positive PEF diurnal variability (≥10% for adults, ≥13% for children), or
      • PEF improvement ≥20% post-bronchodilator, or
      • Post-treatment FEV1 improvement ≥12% and ≥200mL after 4 weeks of therapy within 12 months prior to Visit 1, or
      • Documented FEV1 variability ≥12% and ≥200mL between two stable visits (non-acute, non-infectious states).
    2. For patients diagnosed with bronchial asthma \<1 year prior to enrollment: Require submission of objective documentation within 12 months prior to Visit 1 of any of the above reversibility criteria.
    3. For all enrolled patients meeting inclusion/exclusion criteria: Bronchodilator testing will be conducted during the screening period to establish baseline data for further analysis.
  • Prior to screening (Visit 1, Week -1 to Week 0), patients must have either a documented asthma diagnosis for >6 months or a history of ICS/LABA use for >6 months.

    4. Documented diagnosis of severe eosinophilic asthma (EOS≥150 cells/μL at enrollment, and if EOS 150-\<300 cells/μL at enrollment, must have EOS≥300 cells/μL at sometime within 1 year before enrollment) 5. Documented current maintenance treatment with MD/HD ICS + LABA with up to one additional controller

  • Other acceptable asthma controller includes LTRA and LAMA 6. On stable MD/HD ICS(>250μg fluticasone propionate dry powder formulation equivalents total daily dose) + LABA for ≥2 months prior to enrollment (see Appendix F for medium and high daily ICS doses by formulation) 7. For patients on MD ICS/LABA, stable LTRA or LAMA (≥2 weeks) is allowed 8. Documented at least one exacerbation in the year prior to enrolment
  • A qualifying historical asthma exacerbation is a symptomatic worsening requiring systemic (i.e., oral, intravenous (IV) or intramuscular; any healthcare setting or temporary increase from a stable maintenance dose of oral corticosteroid) or that resulted in hospitalization or emergency room/urgent care visit.

    • Source documentation is required for physician-diagnosed asthma, ICS-LABA use and asthma exacerbations over the prior year. A patient verbal history suggestive of asthma symptoms and/or prior asthma exacerbations, but without supporting documentation, is not sufficient to satisfy these inclusion criteria.
    • Examples of acceptable documentation of the asthma disease state and prior asthma exacerbations include clinic visit (primary or specialist Health care provider (HCP)), emergency room/urgent care, or hospital records listing asthma as a current problem, plus documentation of at least 1 asthma exacerbations during the 12 months prior to ICF.

Weight 9. Weight of ≥40 kg. Sex and /Barrier Requirements 10. Male and/or female Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

  • Female patients:
  • Females not of are defined as females who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are . Females will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to Visit 1(Week -1 to Week 0) without an alternative medical cause. The following age-specific requirements apply:
  • Females \< 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and FSH levels in the postmenopausal range.
  • Females ≥ 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.
  • Female patients of childbearing potential must use one highly effective form of birth control. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. Females of childbearing potential who are sexually active with a non-sterilised male partner must agree to use one highly effective method of birth control, as defined below, from enrolment throughout the study and until at least 12 weeks after last dose of study intervention. Cessation of contraception after this point should be discussed with a responsible physician.
  • The following are not acceptable methods of contraception: periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea. Female condom and male condom should not be used together.
  • All WOCBP must have a negative serum pregnancy test result at Visit 1(Week -1 to Week 0).
  • Highly effective birth control methods include: Total sexual abstinence is an acceptable method provided it is the usual lifestyle of the patient (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments) [(periodic abstinence eg, calendar, ovulation,symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to study intervention, and withdrawal are not acceptable methods of contraception], a vasectomised partner, Implanon®, bilateral tubal occlusion, intrauterine device/levonorgestrel intrauterine system, Depo-Provera™ injections, oral contraceptive, and Evra Patch™, Xulane™, or NuvaRing®.

Exclusion Criteria:

Medical Conditions

  1. Unable to commit to the scheduled visits as required by the protocol, or unable to commit to undergoing protocol guided reductions in asthma therapy, as directed by the Investigator.
  2. pulmonary disease other than asthma (e.g., active lung infection, [COPD], bronchiectasis, pulmonary fibrosis, cystic fibrosis), or ever been diagnosed with pulmonary or systemic disease, other than asthma, that is associated with elevated peripheral eosinophil counts (e.g., allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).

    •Within the 12 months prior to Visit 1, a CT scan is required to exclude related diseases.

  3. Current smokers at Visit 1 are not allowed. Former smokers with smoking history ≥ 10 pack-years at Visit 1 are not allowed; Former smokers with a smoking history of \<10 pack years must have stopped for at least 6 months to be eligible.
  4. History of alcohol or drug abuse within 12 months prior to Visit 1(Week -1 to Week 0).
  5. A helminth parasitic infection diagnosed within 24 weeks prior to Visit 1(Week -1 to Week 0) that has not been treated with, or has failed to respond to, standard of care therapy.
  6. History of anaphylaxis to any biologic therapy.
  7. Known history of allergy or reaction to any component of the study treatment formulation.
  8. Respiratory exacerbation requiring use of Systemic corticosteroids (SCS) or acute upper/lower respiratory infection that required antibiotics or antiviral medication within 30 days prior to Visit 1(Week -1 to Week 0). An extension of the screening period up to 3 months is allowed to ensure that a patient recovering from any repiratory exacerbation or acute upper/lower respiratory infection can be included.
  9. A history of known immunodeficiency disorder, including .
  10. Current or history of within 5 years before the screening visit with the following exceptions:

    • In-situ carcinoma of the cervix where curative therapy has been completed and patients are in remission for at least 12 months prior to screening.
    • Basal cell or superficial squamous skin cancer.
    • Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained.
  11. Exclusion for any of the following:

    • Previous bone marrow transplant.
    • Non-leucocyte depleted whole blood transfusion within 120 days of genetic sample collection.
  12. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

    1. Affect the safety of the patient throughout the study,
    2. Confound the study results or impact the scientific validity of the data outcome, or
    3. Impede the patient's ability to complete the entire duration of study.

    Prior/Concomitant Therapy

  13. Oral corticosteroid use during 4 weeks prior to Visit 1(Week -1 to Week 0).
  14. Use of medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, or any experimental anti-inflammatory therapy) within 3 months or 5 halflives (whichever is longer) prior to the date informed consent is obtained.
  15. Receipt of any marketed or biologic agent within 4 months or 5 half lives (whichever is longer) prior to Visit 1(Week -1 to Week 0) or receipt of any investigational non biologic agent within 30 days or 5 half-lives (whichever is longest) prior to Visit 1(Week -1 to Week 0). Exception:

    1. For marketed non-respiratory biologics, it is allowed if the patient is stable on treatment for at least 3 months prior to Visit 1(Week -1 to Week 0) and throughout the study.
    2. Covid-related prevention and treatment
  16. Receipt of 30 days prior to the date of first dose of benralizumab.
  17. Intention to use any concomitant medication that is not permitted or failure to complete the required for a particular prohibited medication.
  18. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained.
  19. Received bronchial thermoplasty (BT) as treatment of asthma within 12 months prior to Visit 1.
  20. Received treatment with traditional Chinese herbs or proprietary Chinese medicines that have anti-asthmatic effects (excluding topical Chinese herbs) within 4 weeks prior to Visit 1 (Week -1 to Week 0) Prior/Concurrent Clinical Study Experience
  21. Concurrent participation in another clinical study with an Investigational Product or a post-authorization safety study.

    Diagnostic Assessments

  22. Any clinically significant abnormal findings in physical examination, medical history, vital signs, haematology, or clinical chemistry during the enrolment period, which in the opinion of the investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete the entire duration of the study.

    Other Exclusions

  23. For females only - currently pregnant (confirmed with positive pregnancy test), breast-feeding, or lactating.
  24. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  25. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  26. Previous enrolment in the present study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
504 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be all treated by study Drug.

    Drug: Benralizumab

Interventions

  • Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be enrolled into this single arm treatment.

    Also known as: Fasenra

06

What researchers measure

Primary outcomes

  1. To assess the potential for benralizumab treated patients to reduce their standard of care asthma controller regimen in the overall patient populationa and by subgroups of baseline background therapy

    Main outcomes: Proportion of patients with at least one controller medication category reduction at end of reduction phase * discontinuation of LTRA, or * discontinuation of LAMA, or * getting to MD ICS/LABA or * getting to LD ICS/LABA Supportive outcomes: * Proportion of patients with individual category reduction at end of reduction phase * Proportion of patients with ≥2 category reductions in controller medication * In sub-group of patients who meet reduction criteria * proportion of patients with at least one controller medication category reduction, * proportion of patients with individual category reduction * proportion of patients with ≥2 reductions in controller medication at end of reduction phase

    Time frame: within 40 weeks after the first administration

Secondary outcomes

  1. To assess standard asthma efficacy measures for benralizumab treated patients when reducing their standard of care asthma controller regimen in the overall patient population a and by subgroups of baseline background therapy

    * Change in pre-BD FEV1 from beginning of reduction phase to end of reduction phase * Change in ACQ-5 and SGRQ from beginning of reduction phase to end of reduction phase * Proportion of patients with no deterioration (defined as ACQ-5 change \<0.5 since last visit and FEV1 \< -100mL compared to beginning of reduction phase) during reduction phase

    Time frame: From 16~40 weeks

  2. To assess if reductions in background therapies achieved at end of reduction phase aremaintained until end of maintenance phase in the overall patient population a and by subgroups of baseline background therapy

    •Proportion of patients at the end of the maintenance phase who use the same background therapy that they achieved at the end of the reduction phase

    Time frame: From 32-56 weeks

  3. To assess standard asthma efficacy measures for benralizumab treated patients at induction phase in the overall patient population and by subgroups of baseline background therapy

    * Change in FEV1 from beginning of induction phase to end of induction phase * Change in ACQ-5 and SGRQ from beginning of induction phase to end of induction phase * Proportion of patients achieving ACQ-5 MCID improvement (defined as change in ACQ-5 ≤-0.5 compared to beginning of induction phase) and SGRQ MCID improvement (defined as change in SGRQ ≤-4 compared to beginning of induction phase) during induction phase

    Time frame: from 0-16 weeks

  4. To assess overall asthma exacerbation rate during the study of severe eosinophilic asthma patients treated with benralizumab in the overall patient population and by subgroups of baseline background therapy

    * Annualized asthma exacerbation rate during the study (from first dose to EOT) and 1-year baseline period * Change in annualized asthma exacerbation rate during study phase vs. 1-year baseline period Annualized asthma exacerbation rate Defined as Number of exacerbations×365.25/(Follow-Up Date-First Benralizumab dose date+1)

    Time frame: within 56 weeks after first administration

  5. To assess biomarkers of severe eosinophilic asthma patients treated with benralizumab in the overall patient population and by subgroups of baseline background therapy

    Baseline and follow-up visits, and change from baseline: * Blood EOS * FeNO * Total IgE

    Time frame: from -1 week to 56 week

  6. To assess if reductions in background therapies achieved at end of reduction phase aremaintained until end of maintenance phase in the overall patient population a and by subgroups of baseline background therapy

    •Change in ACQ-5, SGRQ and FEV1 from the end of the reduction phase to the end of the maintenance phase

    Time frame: From 40-56 weeks

Other outcomes

  1. To assess the changes in small - airway lung function indicators among patients treated with benralizumab in the overall patient populationa and by subgroups of baseline background therapy over the course of the study

    Change in small - airway lung function indicators from baseline to the end of the maintenance phase: * FEF 50% * FEF 75% * MMEF&MMEF%pred

    Time frame: from -1 week to 56 week

  2. To explore relationship between baseline characteristic and asthma control level at baseline

    Baseline characteristics and asthma control levels at baseline

    Time frame: -1 week

  3. To assess the safety and tolerability of benralizumab during the study in patients with severe eosinophilic asthma, while reducing their standard of care asthma controller regimen and maintaining asthma symptom control

    Frequency of Adverse Events/Serious Adverse Events

    Time frame: from -1 week to 60 week

  4. To assess the safety and tolerability of benralizumab during the study in patients with severe eosinophilic asthma, while reducing their standard of care asthma controller regimen and maintaining asthma symptom control

    Vital Signsb

    Time frame: from -1 week to 56 week

  5. To assess the safety and tolerability of benralizumab during the study in patients with severe eosinophilic asthma, while reducing their standard of care asthma controller regimen and maintaining asthma symptom control

    Laboratory variables (chemistry and hematology)

    Time frame: -1 week, 16 week, 40 week, 56 week

07

Study locations

74 sites
  • Research Site
    Beijing, 100020, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changsha, 410005, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410011, China
  • Research Site
    Chengdu, 610014, China
  • Research Site
    Chengdu, 610021, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Chongqing, 402260, China
  • Research Site
    Guangzhou, 510163, China
  • Research Site
    Guangzhou, 510280, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Guangzhou, 510630, China
  • Research Site
    Guilin, 541001, China
  • Research Site
    Guiyang, 510630, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hefei, 230061, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Hohhot, 010010, China
  • Research Site
    Hohhot, 10050, China
  • Research Site
    Huzhou, 313003, China
  • Research Site
    Jinan, 250012, China
  • Research Site
    Jinan, 250014, China
  • Research Site
    Jinan, 250030, China
  • Research Site
    Kunming, CN-650034, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Luoyang, 471000, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanjing, 211100, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Qingdao, 266042, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200065, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Shanghai, 200092, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenyang, 110004, China
  • Research Site
    Shenzhen, 518001, China
  • Research Site
    Shenzhen, 518036, China
  • Research Site
    Shenzhen, 518039, China
  • Research Site
    Shenzhen, 518101, China
  • Research Site
    Shijiazhuang, 054001, China
  • Research Site
    Shijiazhuang, 50051, China
  • Research Site
    Suzhou, 215004, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Taiyuan, 030001, China
  • Research Site
    Taiyuan, 030032, China
  • Research Site
    Tangshan, 63000, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Tianjin, 300192, China
  • Research Site
    Tianjin, 300222, China
  • Research Site
    Weifang, 261000, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430010, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430060, China
  • Research Site
    Wuhu, 241000, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xi'an, 710068, China
  • Research Site
    Xi'an, 710100, China
  • Research Site
    Xiamen, 361004, China
  • Research Site
    Xinxiang, 453100, China
  • Research Site
    Xuzhou, 221009, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhangzhou, 363000, China
  • Research Site
    Zhengzhou, 450003, China
  • Research Site
    Zhengzhou, 450007, China
  • Research Site
    Zhengzhou, 450052, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in May 2026, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Jun 18, 2024
StartActual
Feb 28, 2024
Primary completionActual
May 13, 2026
CompletionActual
May 13, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06465485
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 18, 2024
Start date
Feb 28, 2024
Primary completion
May 13, 2026
Completion
May 13, 2026
Last update
Sep 3, 2026

Study contacts

Min Zhang, Professor
principal investigator · ShangHai First General Hospital
HuaHao Shen, Professor
principal investigator · Second Affiliated Hospital, Zhejiang University, School of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion